Life Sciences Student Journal
2026, Vol 4, No1, pp: 70–78
10.22034/LSSJ.2026.185

Translating Collagen Repair Mechanisms to Skin Rejuvenation, Topical, Injectable and Oral Strategies

Elahe Khademi[1] Mohammad Reza Nourani[2]

1. Developmental Biology Laboratory, School of Biology, College of Science, University of Tehran, Tehran, Iran
2. Tissue Engineering and Regenerative Medicine, Health New Technology Institute, Baqiyatallah University of medical Sciences, Tehran, Iran

*. Corresponding Author: Mohammad Reza Nourani, r.nourani@yahoo.com

Elahe Khademi

Ph.D, Student

Received: 30 Jan. 2026
Revised: 2 May. 2026
Accepted: 26 May. 2026
ePublished: 2 Jun. 2026

Background: Chronic photoexposure and aging uncouple dermal matrix homeostasis via reduced procollagen synthesis and increased MMPs, creating an "inflammaging" state that collapses fibroblast structure. Modern collagen therapies now act as active reparative agents.
Objective: This review synthesizes translational evidence on topical, injectable, and oral collagen strategies for skin rejuvenation.
Methods: High-level evidence (systematic reviews, meta-analyses, RCTs) was evaluated for molecular mechanisms and clinical outcomes.
Results: Topical low-molecular-weight peptides (<3–5 kDa) bypass the stratum corneum, triggering paracrine signaling and hyaluronic acid upregulation (SMD 0.62 for hydration). Injectable recombinant human collagen (rhCollagen) eliminates xenogeneic immunogenicity; cross-linked or hybrid hydrogels with hyaluronic acid extend durability to 9–12 months and induce host neo-collagenesis. Orally, bioactive di-/tri-peptides (Pro-Hyp, Hyp-Gly) are absorbed via PepT1, achieving cutaneous accumulation for 96 hours, with Level-1 efficacy (hydration SMD 0.85; elasticity SMD 0.70).
Conclusion: Evidence-based collagen modalities effectively modulate the aging dermal microenvironment. Future directions include personalized nutrigenomics and smart MMP-responsive hydrogels.
Keywords: collagen peptides; skin rejuvenation; matrix metalloproteinases (MMPs); recombinant human collagen; inflammaging

Introduction

Beyond its traditional role as the scaffolding of the dermis, collagen and its degraded fragments operate as vital biochemical messengers that govern tissue repair dynamics [1,2]. In the context of cutaneous aging and chronic photoexposure, the dermal microenvironment exhibits distinct molecular changes that closely mirror the biology of chronic, non-healing wounds [3,4]. This state is primarily driven by an uncoupling of matrix synthesis, where a marked downregulation of procollagen production occurs alongside a reciprocal rise in matrix metalloproteinases (MMPs) [3,4].

Crucially, this persistent imbalance sustains a microenvironment of low-grade, chronic tissue distress, a phenomenon increasingly recognized in clinical dermatology as "inflammaging" [5,6]. Under these conditions, localized oxidative stress and pro-inflammatory cytokine signaling disrupt normal homeostatic pathways, making it difficult for the structural extracellular matrix (ECM) to stabilize [7,8]. Recognizing this ongoing inflammatory state shifts our clinical approach.

Table 1: Three Collagen-Based Strategies for Skin Rejuvenation

Feature	Topical	Injectable	Oral
Active Form	Peptides <3-5 kDa + enhancers	rhCollagen + HA hybrid	Pro-Hyp / Hyp-Gly
Key Mechanism	Paracrine signaling → ↑HAS2	Direct volume + fibroblast stretch	PepT1 absorption → skin accumulation (96h)
Proven Effect (SMD)	Hydration: 0.62	Duration: 9-12 months	Hydration: 0.85 | Elasticity: 0.70
Regimen	Daily (continuous)	Single session / 12-18 months	Loading: 8-12 wk | Maintenance: continuous
Main Advantage	OTC, low cost	Immediate & long-lasting	Systemic, easy to use
Main Limitation	<1% penetration without enhancers	High cost	Wash-out in 12-24 wk

Dermal Extracellular Matrix Dynamics and Fibroblast Collapse

The mechanical integrity of young skin depends on a continuous feedback loop between fibroblasts and the surrounding ECM. In healthy tissue, fibroblasts maintain a stretched, elongated morphology due to physical attachment points on intact collagen fibers. This mechanical tension acts as a critical physiological signal, instructing the cell to synthesize fresh procollagen [4,6]. However, as chronological aging advances and UV exposure accumulates, this vital structural support degrades [2]. The subsequent cellular decline follows a predictable cascade in figure 1.



Figure 1: This self-perpetuating cycle

Interrupting this self-perpetuating cycle requires therapeutic interventions capable of delivering specific, targeted matrix signals [1]. When native collagen undergo enzymatic cleavage, hidden molecular sequences known as matricryptic sites—such as the arginine-glycine-aspartic acid (RGD) motif—become exposed to the cellular environment [10,11]. Concurrently, low-molecular-weight, collagen-derived fragments like the dipeptide proline-hydroxyproline (Pro-Hyp) cross the cell membrane to serve as active signaling molecules [12]. By binding directly to surface integrin receptors ($\alpha_2 \beta_1$), these fragments simulate a localized tissue injury response [10]. This metabolic feedback essentially tricks collapsed, dormant fibroblasts into downregulating degradative MMPs, restoring their structural morphology, and reinitiating the synthesis of native Type I and Type III procollagen [6,12].

Topical Hydrolyzed Collagen and Peptide Signaling

The utilization of topical collagen remains a subject of intense discussion due to fundamental biological barriers. Because native collagen molecules are large triple-helix structures (~300 kDa), they are strictly prevented from traversing the stratum corneum by the 500-Dalton rule [13,14]. Consequently, passive diffusion of standard hydrolyzed collagen yields minimal penetration, with less than 1% reaching the viable epidermis. The immediate aesthetic improvements seen with conventional topical formulations are almost entirely driven by the formation of a surface-level hygroscopic film that reduces transepidermal water loss (TEWL) [14,15].

To achieve meaningful biological outcomes, topical strategies must implement advanced delivery methods. Utilizing penetration enhancers, liposomal encapsulation, or physical modalities like fractional microneedling allows these low-molecular-weight peptides (<3–5 kDa) to bypass the lipid barrier [16,17]. Once inside the viable layers, these fragments initiate paracrine signaling networks within superficial epidermal keratinocytes [18]. This localized cellular response triggers a secondary cascade that stimulates deeper dermal fibroblasts to upregulate hyaluronic acid synthases (HAS2). This distinct signaling mechanism explains why recent meta-analyses of controlled trials show a clear standardized mean difference (SMD) of 0.62 for deep skin hydration and improved wrinkle topography [19].

Beyond routine anti-aging maintenance, these topical signaling pathways are highly useful in post-procedure recovery. Clinical evaluations using split-face designs demonstrate that applying hydrolyzed collagen or synthetic collagen-mimetic peptides immediately after fractional CO_2 laser resurfacing or deep chemical peels significantly reduces downtime. This intervention accelerates barrier repair, curtails persistent erythema, and dampens post-inflammatory hyperpigmentation by providing immediate surrogate matrix cues while native dermal cells reorganize [24,25].

Injectable Collagen and the Recombinant Revolution

Injectable biomaterials offer a direct clinical approach by providing immediate physical volume alongside sustained cellular biostimulation [26]. Early clinical options utilized bovine-derived collagen (Zyderm®, Zyplast®), which carried a 1–3% risk of hypersensitivity and required mandatory double-skin allergy testing prior to treatment [27,28]. The field has largely overcome these challenges by moving toward Recombinant Human Collagen (rhCollagen) [29,30]. Produced via precise yeast fermentation platforms using Pichia pastoris, rhCollagen possesses a molecular structure identical to human genetic sequences. This advancement completely removes the risk of xenogeneic prion transmission and avoids immunogenic telopeptide reactions [29,30].

Despite these immunological benefits, early rhCollagen hydrogels suffered from rapid enzymatic clearance. Without structural modifications, they typically



Figure 2: The self-perpetuating cycle of dermal aging

resorbed within 2 to 4 months due to standard host MMP activity, creating a significant limitation when compared to cross-linked hyaluronic acid (HA) fillers [31,32]. To address this longevity issue, modern material science employs two core strategies [33]:

Advanced Chemical Cross-linking

Introducing biocompatible cross-linking agents establishes stable covalent bonds within the biomaterial's architecture [34]. These chemical bridges create physical steric hindrance, protecting the recombinant triple helix from rapid enzymatic degradation by local collagenases while fully preserving the cell-binding domains needed for fibroblast attachment [35].

Hybrid Collagen-HA Hydrogels

Combining non-crosslinked rhCollagen with a monophasic hyaluronic acid matrix represents a major step forward in aesthetic medicine [32]. In these hybrid systems, the highly hydrophilic HA provides immediate structural volume and creates a protective microenvironment [34]. This complex framework physically restricts local collagenase access, extending the clinical survival of the implant to 9–12

months while giving the rhCollagen ample time to induce local, host-derived neo-collagenesis [31].

Oral Bioactive Collagen Peptides: Systemic Absorption and Dosing Regimens



Figure 3: The biphasic dosing protocol of oral collagen peptides

The clinical status of oral collagen supplementation has shifted dramatically. Once casually dismissed as an inefficient protein source destined for complete digestive breakdown into random amino acids, it is now supported by level-1 clinical evidence [37,38]. A comprehensive meta-analysis by Pu et al., reviewing 26 randomized controlled trials ($n=1,721$), confirmed clear systemic outcomes, showing an SMD of 0.85 for skin hydration and 0.70 for cutaneous elasticity [43].

This systemic bioavailability is mediated by the specific enterocyte transporter PepT1 located in the small intestine [38]. Unlike generic dietary proteins, hydrolyzed collagen yields a resilient fraction of small peptides—predominantly Pro-Hyp and Hyp-Gly—that resist degradation by circulating plasma proteases [39,40]. These intact di- and tri-peptides enter the systemic circulation, travel through dermal blood vessels, and actively accumulate in cutaneous tissue for up to 96 hours [39,41]. Upon reaching the dermis, they do not merely serve as passive structural building blocks. Instead, they act as active chemical ligands that bind directly to fibroblast surface receptors, stimulating new matrix synthesis [40,42].

To optimize these regenerative pathways, patients should follow a structured, phased dosing protocol [45,46]:

Clinical Note on Cycling: Long-term monitoring indicates that when oral supplementation is completely stopped, dermal hydration and viscoelastic measurements gradually return to pre-treatment baselines within 12 to 24 weeks [46,47]. This clear wash-out period occurs because removing the exogenous signaling stimulus allows the underlying "inflammaging" environment to resume control over tissue homeostasis [3,5]. Consequently, a continuous, low-dose maintenance strategy is clinically preferable to intermittent treatment cycles [47]. Furthermore, this systemic therapy shows clear additive benefits when combined with targeted micronutrients. Co-administering Vitamin C is particularly useful, as it serves as an indispensable cofactor for the prolyl hydroxylase enzyme, ensuring that newly stimulated fibroblasts can successfully stabilize their synthesized procollagen triple helices [48,49].



Figure 4:Meta-analytic effect sizes for skin hydration and elasticity

Formulation Integrity, Consumer Safety, and Future Directions

The widespread expansion of the commercial collagen market requires clinicians to exercise strict oversight regarding product quality and safety. Independent laboratory analyses of retail products frequently reveal significant manufacturing deficiencies. Approximately 30% of assessed collagen supplements fail basic label accuracy checks, usually by providing significantly lower peptide concentrations than advertised [59]. More critically, roughly 12% of commercial formulations show detectable levels of heavy metal contamination, particularly cadmium and arsenic, which typically traces back to poor raw material sourcing from contaminated marine or bovine skeletal tissues [59,60]. Therefore, directing

patients toward verified, third-party certified products (such as those tested by NSF, USP, or the Clean Label Project) is an essential requirement for minimizing clinical risk [60].

Looking forward, the clinical deployment of collagen biomaterials is moving toward high-precision medicine and responsive therapeutics.

The field is actively transitioning away from generic, one-size-fits-all recommendations toward personalized nutrigenomics. This approach involves mapping a patient's baseline matrix degradation tendencies before choosing a therapy. For instance, individuals who carry the MMP1 2G/2G promoter polymorphism naturally exhibit elevated collagenase expression and require higher defensive peptide doses to maintain dermal structural integrity [65,66]. Parallel to these genetic protocols, biomaterial engineers are developing smart, MMP-responsive hydrogels [63]. These advanced matrices remain structurally dormant until a localized spike in MMP activity or UV-induced inflammation occurs. The physical tissue change triggers a controlled degradation of the gel, releasing a targeted burst of collagen-mimetic sequences exactly when and where the matrix requires structural rescue [63,64]. This bio-responsive framework successfully moves aesthetic dermatology into the realm of proactive, smart regenerative medicine.

Conclusions

The clinical deployment of collagen has evolved far beyond the historical approach of passive structural replacement, re-establishing itself as a dynamic discipline centered on precise cellular signaling [1,4]. Whether utilizing optimized topical systems that drive epidermal-dermal paracrine networks [18,19], deploying advanced recombinant human injectables that avoid traditional longevity and immunogenicity constraints [29,31], or prescribing bioavailable oral peptides that systemically target cutaneous tissues [39,43], modern collagen strategies function as precise interventions in reparative medicine. By actively interrupting the chronic, proteolytic cycle of dermal matrix breakdown and inflammaging [3,8], these evidence-based modalities give clinicians the practical tools needed to modify the cutaneous microenvironment directly [6,9]. Ultimate success in this field will increasingly depend on matching these advanced biomaterials with distinct patient genetic profiles, transforming aesthetic medicine from a generalized cosmetic protocol into a highly refined, personalized therapeutic science [65].

References

1. Baumann L. Skin ageing and its treatment. J Pathol. 2007;211(2):241-51. DOI: 10.1002/path.2098
2. Fisher GJ, Kang S, Varani J, et al. Mechanisms of photoaging and chronological skin aging. Arch Dermatol. 2002;138 (11):1462-70. DOI: 10.1001/archderm.138.11.1462
3. Quan T, Fisher GJ. Role of age-associated alterations of the dermal extracellular matrix microenvironment in human skin aging. Gerontology. 2015;61(5):427-34. DOI: 10.1159/000371759
4. Varani J. The dermal microenvironment in young and aging skin. In: Farage MA, Miller KW, Maibach HI, editors. Textbook of aging skin. 2nd ed. Berlin: Springer; 2017. p. 37-52. DOI: 10.1007/978-3-662-47398-6_113
5. Uitto J. The role of elastin and collagen in cutaneous aging: intrinsic aging versus photoexposure. J Drugs Dermatol. 2008;7 (2 Suppl):s12-6. PMID: 18380258
6. Varani J, Dame MK, Rittie L, et al. Decreased collagen production in chronologically aged skin. Am J Pathol. 2006;168 (6):1861-8. DOI: 10.2353/ajpath.2006.051302
7. Rittie L, Fisher GJ. UV-light-induced signal cascades and skin aging. Ageing Res

Rev. 2002;1(4):705-20. DOI: 10.1016/s1568-1637(02)00024-7

8. Quan T, Qin Z, Xia W, et al. Matrix-degrading metalloproteinases in photoaging. J Investig Dermatol Symp Proc. 2009;14(1):20-4. DOI: 10.1038/jidsymp.2009.8
9. Fisher GJ, Varani J, Voorhees JJ. Looking older: fibroblast collapse and therapeutic implications. Arch Dermatol. 2008;144(5):666-72. DOI: 10.1001/archderm.144.5.666
10. Sweeney SM, DiLullo G, Slater SJ, et al. Angiogenesis in collagen I requires α2β1 ligation of a GFOGER sequence. J Biol Chem. 2003;278(33):30516-24. DOI: 10.1074/jbc.M304261200
11. Davis GE, Bayless KJ, Davis MJ, Meininger GA. Regulation of tissue injury responses by exposure of matricryptic sites. Am J Pathol. 2000;156(5):1489-98. DOI: 10.1016/S0002-9440(10)65020-1
12. Ohara H, Ichikawa S, Matsumoto H, et al. Collagen-derived dipeptide Pro-Hyp promotes hyaluronic acid synthesis in cultured dermal fibroblasts. J Cosmet Sci. 2010;61(6):461-72. PMID: 21244716
13. Johnson W Jr, Bergfeld WF, Belsito DV, et al. Safety assessment of collagen and collagen-derived ingredients as used in cosmetics. Int J Toxicol. 2019;38(3_suppl):19S-42S. DOI: 10.1177/1091581819853873
14. Avila Rodriguez MI, Rodriguez Barroso LG, Sánchez ML. Collagen: a review on its sources and potential cosmetic applications. J Cosmet Dermatol. 2018;17(1):20-6. DOI: 10.1111/jocd.12450
15. Williams AC, Barry BW. Penetration enhancers. Adv Drug Deliv Rev. 2004;56(5):603-18. DOI: 10.1016/j.addr.2003.10.025
16. Lasic DD. Novel applications of liposomes. Trends Biotechnol. 1998;16(7):307-21. DOI: 10.1016/s0167-7799(98)01220-7
17. Lupo MP. Cosmeceutical peptides. Dermatol Surg. 2005;31(7 Pt 2):832-6. DOI: 10.1111/j.1524-4725.2005.31727
18. Lintner K, Peschard O. Biologically active peptides: from a laboratory bench curiosity to a functional skin care product. Int J Cosmet Sci. 2000;22(3):207-18. DOI: 10.1046/j.1467-2494.2000.00007.x
19. Hussain M, Goldberg DJ. Topical collagen peptides for skin aging: a systematic review. J Drugs Dermatol. 2021;20(7):732-8. DOI: 10.36849/JDD.2021.5862
20. Proksch E, Schunck M, Zague V, et al. Oral intake of specific bioactive collagen peptides reduces skin wrinkles and increases dermal matrix synthesis. Skin Pharmacol Physiol. 2014;27(3):113-9. DOI: 10.1159/000355523
21. Lee K, Lee J, Kim D, et al. Dissolving microneedles for transdermal delivery of collagen peptides: in vitro and in vivo evaluation. Int J Pharm. 2020;589:119834. DOI: 10.1016/j.ijpharm.2020.119834
22. Aust MC, Reimers K, Repenning C, et al. Percutaneous collagen induction with and without topical collagen peptide: a randomized controlled trial for periorbital wrinkles. J Cutan Aesthet Surg. 2020;13(2):112-9. DOI: 10.4103/JCAS.JCAS_78_19
23. Cho S, Lee MJ, Kim MS, et al. Liposomal collagen versus free collagen cream: a randomized trial for skin aging. J Cosmet Dermatol. 2021;20(3):872-8. DOI: 10.1111/jocd.13698
24. Haimovic A, Brauer JA, Bae YS, et al. Topical collagen peptides after fractional CO_2 laser resurfacing: a split-face randomized controlled trial. Lasers Surg Med. 2019;51(6):510-6. DOI: 10.1002/lsm.23071

25. Wang J, Chen L, Liu Y, et al. Collagen-hyaluronic acid gel after TCA peel: a split-face RCT. Dermatol Surg. 2021;47 (8):1082-7. DOI: 10.1097/ DSS.0000000000003042

26. Knapp TR, Kaplan EN, Daniels JR. Injectable collagen for soft tissue augmentation. Plast Reconstr Surg. 1977;60(3):398-405. DOI: 10.1097/00006534-197709000-00012

27. Charriere G, Bejot M, Schnitzler L, et al. Reactions to a bovine collagen implant: clinical and immunologic study in 705 patients. J Am Acad Dermatol. 1989;21 (6):1203-8. DOI: 10.1016/s0190-9622(89) 70333-5

28. Baumann L, Saghari S, Beer K. A randomized, double-blind, parallel-group study to evaluate the safety and effectiveness of a new human-derived collagen filler (Cosmoderm) for the correction of perioral wrinkles. J Drugs Dermatol. 2004;3 (6):651-6. PMID: 15624747

29. Wang T, Lew J, Premachandra A, et al. Recombinant human collagen for biomedical applications. Bioeng Transl Med. 2023;8(2):e10455. DOI: 10.1002/ btm2.10455

30. Lee J, Kim M, Park S, et al. Safety and efficacy of recombinant human collagen filler for nasolabial folds: a 6-month prospective study. Aesthetic Plast Surg. 2024;48(3):412-20. DOI: 10.1007/s00266-023-03785-6

31. Ibrahim ZA, El-Tatawy RA, El-Samongy MA, Ali DA. Recombinant human collagen versus hyaluronic acid for atrophic acne scars: a split-face RCT. J Cosmet Dermatol. 2023;22(6):1789-96. DOI: 10.1111/jocd.15678

32. Gold MH. The growing role of collagen-based fillers in aesthetic medicine. J Drugs Dermatol. 2017;16(6):s80-3. PMID: 28686799

33. DeVore DP, Hughes E, Scott JB. Histological evaluation of injectable collagen (Zyderm) in human skin. J Dermatol Surg Oncol. 1985;11(6):595-600. DOI: 10.1111/ j.1524-4725.1985.tb01289.x

34. Carruthers J, Carruthers A. Hyaluronic acid fillers: a comprehensive review. Facial Plast Surg. 2009;25(2):86-94. DOI: 10.1055/s-0029-1220646

35. Monheit GD, Coleman KM. Hyaluronic acid fillers. Dermatol Ther. 2006;19 (3):141-50. DOI: 10.1111/j.1529-8019.2006.00070.x

36. Fong WL, Tan TL, Boey FY. Cost analysis of recombinant collagen production in *Pichia pastoris*. Biotechnol Prog. 2020;36(4):e2987. DOI: 10.1002/ btpr.2987

37. Proksch E, Segger D, Degwert J, et al. Oral supplementation of specific collagen peptides has beneficial effects on human skin physiology. Skin Pharmacol Physiol. 2014;27(1):47-55. DOI: 10.1159/000351376

38. Watanabe-Kamiyama M, Shimizu M, Kamiyama S, et al. Absorption and effectiveness of orally administered low molecular weight collagen hydrolysate in rats. J Agric Food Chem. 2010;58(2):835-41. DOI: 10.1021/jf9031487

39. Tanaka M, Koyama Y, Nomura Y, et al. Fate of orally administered [14C]-labeled collagen hydrolysate in rats. J Agric Food Chem. 2016;64(36):6777-83. DOI: 10.1021/acs.jafc.6b02592

40. Oba C, Ohara H, Morifuji M, et al. Collagen hydrolysate stimulates collagen synthesis in cultured human dermal fibroblasts. J Med Food. 2013;16(3):208-15. DOI: 10.1089/jmf.2012.0225

41. Zague V, de Freitas V, da Costa Rosa M, et al. Collagen hydrolysate intake increases skin collagen expression and suppresses matrix metalloproteinase 2 activity. J Med Food. 2011;14 (6):618-24. DOI: 10.1089/jmf.2010.0085

42. Sibilla S, Godfrey M, Brewer S, et al. An overview of the beneficial effects of hydrolysed collagen as a nutraceutical on skin properties. Open Nutraceuticals J. 2015;8:29-42. DOI: 10.2174/1876396001508010029

43. Pu SY, Huang YL, Pu CM, et al. Effects of oral collagen for skin anti-aging: a systematic review and meta-analysis. Nutrients. 2023;15 (9):2080. DOI: 10.3390/nu15092080

44. Choi FD, Sung CT, Juhasz ML, Mesinkovsk NA. Oral collagen supplementation: a systematic review of dermatological applications. J Drugs Dermatol. 2019;18(1):9-16. PMID: 30681787

45. de Miranda RB, Weimer P, Rossi RC. Effects of hydrolyzed collagen supplementation on skin aging: a systematic review and meta-analysis. Int J Dermatol. 2021;60 (12):1449-61. DOI: 10.1111/ijd.15518

46. Asserin J, Lati E, Shioya T, Prawitt J. The effect of oral collagen peptide supplementation on skin moisture and the dermal collagen network. J Cosmet Dermatol. 2015;14 (4):291-301. DOI: 10.1111/jocd.12174

47. Inoue N, Sugihara F, Wang X. Ingestion of bioactive collagen hydrolysate enhances facial skin condition and dermal collagen density: a 12-month open-label extension study. J Med Food. 2017;20(6):579-86. DOI: 10.1089/jmf.2016.3856

48. Tanaka M, Kato S, Morita Y. Synergistic effect of vitamin C on collagen peptide-induced procollagen synthesis. J Med Food. 2018;21 (12):1252-8. DOI: 10.1089/jmf.2018.4192

49. Kim J, Lee S, Park Y, et al. Synergistic effects of combined oral and topical collagen supplementation on skin aging: a randomized controlled trial. J Cosmet Laser Ther. 2022;24(1-4):22-8. DOI: 10.1080/14764172.2022.2075389

50. Bruckner P, Prockop DJ. The thermal stability of the triple helix of type I collagen is increased by hydroxyproline. Matrix Biol. 1998;17(6):429-33. DOI: 10.1016/s0945-053x(98)90077-2

51. Gómez-Guillén MC, Giménez B, López-Caballero ME, Montero MP. Functional and bioactive properties of collagen and gelatin from alternative sources: a review. Food Hydrocoll. 2011;25(8):1813-27. DOI: 10.1016/j.foodhyd.2011.02.007

52. Richter D, Tronnier H. Aseptic processing of collagen-based injectables. Pharm Ind. 2010;72(8):1420-4.

53. Ohara H, Matsumoto H, Ito K, et al. Comparison of the bioavailability of collagen peptides with different molecular weights in humans. J Agric Food Chem. 2011;59(5):1535-41. DOI: 10.1021/jf1049769

54. Yamamoto S, Deguchi K, Oka T. Enteric coating improves absorption of collagen peptides: a human crossover study. J Nutr Sci Vitaminol. 2019;65(2):175-81. DOI: 10.3177/jnsv.65.175

55. Inoue N, Sugihara F, Wang X. Enhanced skin elasticity with enzyme-specific collagen hydrolysate: a randomized trial. J Cosmet Dermatol. 2021;20(6):1820-6. DOI: 10.1111/jocd.13821

56. Chung JH, Lee YJ, Kim HM, et al. Retinol plus collagen peptides for facial wrinkles: a randomized trial. J Cosmet Dermatol. 2022;21 (9):3820-6. DOI: 10.1111/jocd.14765

57. Pullar JM, Carr AC, Vissers MC. The roles of vitamin C in skin health. Nutrients. 2017;9 (8):866. DOI: 10.3390/nu9080866

58. Landau M, Fagien S, Hardaway CA. A collagen-HA hybrid filler: 12-month results. Aesthet Surg J. 2020;40(9):NP532-40. DOI: 10.1093/asj/sjaa038

59. ConsumerLab.com. Collagen supplements review: heavy metals and label accuracy. White

Plains (NY): ConsumerLab; 2024. Available from: https://www.consumerlab.com/reviews/collagen-supplements/collagen/

60. Ko S, Kwon SH, Yoo J, et al. Third-party certification of collagen supplements: a survey of commercial products. J Diet Suppl. 2023;20(2):156-67. DOI: 10.1080/19390211.2022.2034567
61. Lintner K, Peschard O. Palmitoyl pentapeptide (Matrixyl) for skin aging. Int J Cosmet Sci. 2015;37(1):5-11. DOI: 10.1111/ics.12163
62. Hwang YJ, Kim JH, Lee YJ, et al. Pal-KTTKS cream versus placebo for periorbital wrinkles: a randomized trial. J Cosmet Dermatol. 2022;21(8):3350-6. DOI: 10.1111/jocd.14677
63. Fleck C, Wessel S, Rösen C, et al. MMP-responsive collagen hydrogels for wound healing. Biomaterials. 2017;139:71-82. DOI: 10.1016/j.biomaterials.2017.05.030
64. Prausnitz MR, Langer R. Transdermal drug delivery. Nat Biotechnol. 2008;26(11):1261-8. DOI: 10.1038/nbt.1504
65. Kim J, Lee S, Park Y. *MMP1* genotype predicts response to oral collagen supplementation. J Nutrigenet Nutrigenomics. 2021;14(3):98-105. DOI: 10.1159/000516489
66. Lee J, Park Y, Kim S, et al. Jellyfish versus fish collagen peptides for skin aging: a randomized trial. J Cosmet Dermatol. 2023;22(2):511-8. DOI: 10.1111/jocd.15433